|Price Per Pill or Unit
|US$ 42.6610%US$ 47.40
|US$ 60.4415%US$ 71.10
|US Brand Name
|Voglibose / Repaglinide
|Ajanta Pharma India
Volibo R 0.3/0.5mg is a combination of two antidiabetic medicines namely Repaglinide and Voglibose. The combination drug lowers the amount of glucose (sugar) and reduces associated health complications. Diabetes treatments include medicines that increase the amount of insulin secreted by the pancreas or medicines that decrease the rate at which glucose is absorbed from the gastrointestinal tract. Patients with diabetes have an increased risk of serious health complications, including myocardial infarction, vision loss, stroke, kidney failure, and premature death. Management of type 2 diabetes includes medicinal treatment and healthy eating, regular exercise, weight loss, and blood sugar monitoring. These steps will blood glucose levels closer to normal, which can delay or prevent complications. Volibo R improves hyperglycemia (high blood sugar) in diabetes patients when only diet and exercise or other hypoglycaemic drugs do not achieve adequate glycemic control.
The medicine will vary by your condition and how well the medicine controls your blood glucose levels.
Usually, Volibo R tablets are orally administered in a single dose. If the effect is not sufficient, the quantity of a single dose may be increased by your doctor. Talk to your doctor to get the correct dosing regimen of the antidiabetic medicine. Since elderly patients have a physiological hypofunction, caution should be taken while administering Volibo R. Dose adjustment may be required in patients with liver disease. Furthermore, this antidiabetic medicine should be carefully administered under close observation through the course of the disease with careful attention to the blood sugar level.
Volibo R 0.3/0.5 mg should not be used in patients with hypersensitivity to Voglibose or Repaglinide or any excipients. Patients with diabetic ketoacidosis, severe infection, and gastrointestinal obstruction should also avoid the intake of this oral antidiabetic agent. Antidiabetic medicine may be unsafe to use during pregnancy. Although limited evidence is available that shows harmful effects on the developing baby. Your doctor will decide whether it is safe to take Volibo R during pregnancy or not.
Most side effects of Volibo R 0.3/0.5 mg S do not require any medical advice and resolves within a few days as your body adjusts to the medicine. Talk to your doctor if they persist or become troublesome. Volibo R 0.3/0.5 mg common side effects include diarrhoea, flatulence, stomach pain, skin rash, and hypoglycaemia (low blood glucose).